LaBarge (US) moves to transdermal delivery trials:
This article was originally published in Clinica
Executive Summary
LaBarge (US) has received US FDA permission to undertake trials of its Laser Lancet transdermal drug delivery technology. Preclinical research has shown that the system can significantly increase the permeability of skin to insulin, interferon and hydrocortisone, the company says. The Laser Lancet has also been used to improve the onset of lidocaine local anaesthesia.